Two-year data on the use of intravascular lithotripsy (IVL) in calcified peripheral disease treatment, an advertorial sponsored by Bentley exploring the role of bridging stents in complex aortic procedures, and new guidelines on the management of atherosclerotic carotid and vertebral artery disease piqued readers’ interest in May.
Shockwave Medical recently announced that long-term data from the Disrupt PAD III trial found that superior vessel preparation with intravascular lithotripsy (IVL) led to excellent long-term outcomes out to two years with preservation of future treatment options compared to percutaneous transluminal angioplasty (PTA) in the treatment of calcified peripheral arterial disease (PAD).
At the 2022 Charing Cross (CX) International Symposium (26–28 April, London, UK), Tom Carrell (Cydar Medical, Barrington, UK) delivered a Podium 1st presentation titled “Making endovascular aortic repair outcomes more predictable: Artificial intelligence [AI] takes on a 20-year-old challenge”.
Results from the multicentre, retrospective ODYSSEUS study carried out in The Netherlands suggest that less frequent surveillance after endovascular aneurysm repair (EVAR) may be warranted. However, authors Anna C M Geraedts (Amsterdam University Medical Centres, Amsterdam, The Netherlands) and colleagues stress that future studies are needed to determine the patient groups in which this would be safe.
This advertorial is sponsored by Bentley.
Bridging stents have been used in fenestrated and branched endovascular aneurysm repair (F/BEVAR) for many years. However, their use has always been off-label. In cooperation with Bentley, two investigator-initiated studies are set to create the necessary evidence to shift the use of balloon-expandable covered stents from off-label to on-label in complex aortic procedures.
iVascular has announced the initiation of its first trial with the new generation covered stent iCover—the iliCo study. The study has the objective of evaluating the safety and effectiveness of iCover for the treatment of de novo aorto-iliac atherosclerotic lesions in patients with symptomatic arteriopathy of the lower limbs.
New long-term data from the SAFE-PAD (Safety assessment of femoropopliteal endovascular treatment with paclitaxel-coated devices) study were presented as late-breaking clinical research at the Society for Cardiovascular Angiography & Interventions (SCAI) 2022 Scientific Sessions (19–22 May, Atlanta, USA).
At the time of carotid endarterectomy (CEA), surgeons should consider single antiplatelet therapy (SAPT) rather than dual antiplatelet therapy (DAPT). This is the conclusion of a new meta-analysis—reportedly the largest conducted on the topic to date—published in the European Journal of Vascular and Endovascular Surgery (EJVES).
Silk Road Medical recently announced that the US Food and Drug Administration (FDA) approved expanded indications for the company’s Enroute stent to include patients at standard risk for adverse events from carotid endarterectomy (CEA). Previously, the stent was approved for use only in patients with anatomic or physiological criteria that put them at high risk of complications from more invasive surgical procedures.
The European Society for Vascular Surgery (ESVS) has released 2023 clinical practice guidelines on the management of atherosclerotic carotid and vertebral artery disease. The guideline document, authored by chairperson Ross Naylor (Leicester Vascular Institute, Leicester, UK), co-chairperson Barbara Rantner (Ludwig Maximilian University of Munich, Munich, Germany) et al, was published online ahead of print in the European Journal of Vascular and Endovascular Surgery (EJVES).
The results of a small-scale pilot study from Asia have indicated “potentially disappointing” results with a novel drug-eluting balloon in treating dysfunctional arteriovenous access for dialysis. These findings were delivered by Tjun Tang (Singapore General Hospital, Singapore)—who also highlighted “excellent” technical and clinical success rates and positive safety outcomes—via a Podium 1st presentation at the 2022 Charing Cross (CX) International Symposium (26–28 April, London, UK).